Replies to post #2946 on Keryx Biopharmaceuticals Inc fka KERX

[naturalborninvestor]

How is this undervalued? They are making $9m in product sales while generating $24m in cash operating expenses plus $7 million in R&D per quarter.
Yes, sales are growing, but they are living off convertible notes financing. Not healthy.